Abstract
Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant treatment. The current gold standard of combined pathological and molecular profiling is costly, hampering implementation. We developed HECTOR (Histopathology-based Endometrial Cancer Tailored Outcome Risk), a multimodal deep learning prognostic model using hematoxylin-and-eosin-stained whole-slide-images and tumor stage as input, on 1,912 patients from seven EC cohorts including the PORTEC-1/-2/-3 randomized trials. HECTOR demonstrated C-indices in internal (n = 353) and external (n = 151) test sets of 0.788 and 0.816 respectively, outperforming the current gold-standard, and identified patients with markedly different outcomes (10-year distant recurrence-free probabilities of 97.0%, 77.7% and 58.1% for HECTOR low, intermediate and high risk groups). HECTOR also predicted adjuvant chemotherapy benefit better than current methods. Morphological and genomic feature extraction identified correlates of HECTOR risk groups, some with therapeutic potential. HECTOR improves on the current gold-standard and may help delivery of personalized treatment in EC.
Competing Interest Statement
S.FV., N.H., V.H.K, and T.B. are co-inventors on the patent application number 23315438.4. N.H. declares to have received research grants from the Dutch Cancer Society (DCS) and Varian (paid to institution) unrelated to the current study. C.deK. declares KWF and ZonMW grants unrelated to the project. A.L. received funded research unrelated to the current study from AZ, Clovis, GSK, MSD, Ability, Zentalis, Agenus, Lovance, Sanofi, Roche, OSEimmuno, BMS; is an advisory board member or consultant for AZ, Clovis, GSK, MSD, Merck Serono, Ability, Zentalis, Agenus, and Blueprint; received honoraria and compensation for expenses from AZ, Clovis, and GSK. R.A.N. declared research grants unrelated to the current study to institution from Elekta, Varian, Accuray, Sensius; is an advisory board of MSD. M.B. received grants from the Dutch Cancer Society (KWF), the European Research Council (ERC), Health Holland (HH), Mendus, BioNovion, Aduro Biotech, Vicinivax, Genmab and IMMIOS (all paid to the institute) unrelated to the current study; received non-financial support from BioNTech, Surflay Nanotec and Merck Sharp & Dohme; is a stock option holder in Sairopa. D.C. is part of an advisory board of MSD; received research funding unrelated to the project of HalioDx and Veracyte (to TransSCOT consortium); spouse of an Amgen employee; affiliated to the Wellcome Centre for Human Genetics and NIHR Oxford BRC; received funding from Oxford NIHR Comprehensive Biomedical Research Centre (BRC) and Cancer Research UK (CRUK) Advanced Clinician Scientist Fellowship (C26642/A27963). C.L.C. received grants from the Dutch cancer Society for the PORTEC-1,2,3,4a, RAINBO trials and research grant for translational work on PORTEC; has leadership roles chair of GCIG Endometrial Cancer Committee. V.H.K. declared being an invited speaker for Sharing Progress in Cancer Care (SPCC) and Indica Labs; advisory board of Takeda; sponsored research agreements with Roche and IAG all unrelated to the current study. T.B. received grants unrelated to this work by the DCS. The remaining authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health.
Funding Statement
This work was supported by a translational research project grant from the Hanarth Foundation and the Swiss Federal Institutes of Technology (strategic focus area of personalized health and related technologies; 2021-367) and a grant from the Promedica Foundation (F-87701-41-01) during the conduct of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PORTEC-1/-2/-3 study protocols were approved by the Medical Ethical Committee Leiden – Den Haag – Delft and the medical ethics committees at participating centers. Both studies were conducted in accordance with the principles of the Declaration of Helsinki. All patients provided signed informed consent to study participation. For the retrospective use of the clinical trials and retrospective cohorts (TransPORTEC study, MST), we have obtained ethical permission to use the data by the Medical Ethical Committee Leiden – Den Haag – Delft (B21.065 and B21.011) as well as the Leiden Cohort (nWMO‐D4‐2023‐002), and the Danish Cohort by the Center for Regional Udvikling – De Videnskabsetiske Komiteer(H-16025909).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
